Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04305691 · ClinicalTrials.gov registry record · Phase 2

Trial of Ixazomib for Kaposi Sarcoma

A Phase 2 study of Kaposi Sarcoma and Skin, sponsored by AIDS Malignancy Consortium.

Recruiting
Registry status
Phase 2
Development phase
41
Enrollment target
11
Study locations

NCT04305691 is a Phase 2 study of Kaposi Sarcoma and Skin that is actively recruiting participants, run by AIDS Malignancy Consortium. The registered enrollment target is 41 participants, below the 99-participant average among 13 other Kaposi Sarcoma trials with a reported enrollment target (59% lower). The trial reports 11 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04305691, a Phase 2 study of Kaposi Sarcoma and Skin, is actively recruiting participants, sponsored by AIDS Malignancy Consortium.

RECRUITING
Registry status
Phase 2
Development phase
41 participants
Enrollment target
11
Study locations

Study Summary

This phase II trial studies how well ixazomib works in treating patients with Kaposi sarcoma. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions Studied

Kaposi Sarcoma Skin

Interventions

  • OTHER Quality-of-Life Assessment
  • OTHER Questionnaire Administration
  • DRUG Ixazomib Citrate

Study Locations (11)

California

  • UC San Diego - San Diego
  • Zuckerberg San Francisco General Hospital - San Francisco

Texas

  • Thomas Street Clinic - Houston
  • Thomas Street Clinic - Houston

Florida

  • University of Miami Miller School of Medicine - Miami

Illinois

  • University of Illinois Cancer Center - Chicago

Maryland

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore

Missouri

  • Washington University - St Louis

New York

  • Mount Sinai Hospital - New York

Pennsylvania

  • Abramson Cancer Center at Pennsylvania Hospital - Philadelphia

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2023-11-07
Est. Completion 2029-03-15
Phase Phase 2

Sponsor

AIDS Malignancy Consortium

45 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04305691

The ClinicalTrials.gov registry entry for NCT04305691 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 99-participant average among 13 other Kaposi Sarcoma trials with a reported enrollment target (59% lower). The listed sponsor is AIDS Malignancy Consortium, which has 45 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Kaposi Sarcoma appearing as the primary indexed condition, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.

NCT04305691 reports 11 study locations spanning 9 distinct geographic areas - top geographies include California, Texas, Florida.

Frequently Asked Questions

What is clinical trial NCT04305691 about?

NCT04305691 is a clinical study titled "Trial of Ixazomib for Kaposi Sarcoma". This phase II trial studies how well ixazomib works in treating patients with Kaposi sarcoma. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

What is the current status of trial NCT04305691?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2023-11-07. Estimated completion is 2029-03-15.

What conditions does trial NCT04305691 study?

This clinical trial studies the following conditions: Kaposi Sarcoma, Skin.

What interventions are being tested in trial NCT04305691?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Ixazomib Citrate (DRUG).

Who is sponsoring clinical trial NCT04305691?

This trial is sponsored by AIDS Malignancy Consortium, which has 45 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04305691 being conducted?

This trial has 11 study locations across California, Florida, Illinois, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Kaposi Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Kaposi Sarcoma

All registered trials for this condition

Skin

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.